Cargando…
Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
IMPORTANCE: Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery. OBJECTIVE: To assess the c...
Autores principales: | Lim, Myong Cheol, Chang, Suk-Joon, Park, Boram, Yoo, Heon Jong, Yoo, Chong Woo, Nam, Byung Ho, Park, Sang-Yoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908225/ https://www.ncbi.nlm.nih.gov/pubmed/35262624 http://dx.doi.org/10.1001/jamasurg.2022.0143 |
Ejemplares similares
-
Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020) -
Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons
por: Yoo, Heon Jong, et al.
Publicado: (2018) -
Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)
por: Kim, Ji Hyun, et al.
Publicado: (2022) -
Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019)